Key result
H-FABP testing did not provide any statistically significant improvement in the early diagnosis and exclusion of acute coronary syndrome when used alone or in combination with routinely used biomarkers.
Why the study?
Does H-FABP testing improve the diagnostic accuracy for early diagnosis of acute coronary syndrome in emergency department patients with chest pain?
Cross-Sectional (n=66)
No
Does H-FABP testing improve the diagnostic accuracy for early diagnosis of acute coronary syndrome in emergency department patients with chest pain?
Absolute Event Rate: 0.61% vs 0.51%
p-value: p=>0.05
H-FABP does not significantly improve the early diagnosis or exclusion of acute coronary syndrome when added to routine biomarkers like troponin, CK-MB, and myoglobin.
H-FABP adds no diagnostic value to standard biomarkers for early ACS; leaves open need for prospective trials of alternative markers.
OBJECTIVE: The aim of this study is testing the value of H-FABP in the early diagnosis of ACS alone or with routinely used biomarkers such as myoglobin, CK-MB, and cTn I in patients who admitted to emergency department (ED) with complaint of chest pain and suspected acute coronary syndrome. MATERIAL AND METHODS: This prospective and cross-sectional study was performed at the Emergency Department of University hospital between June 2009 and September 2010. Patients who were admitted with chest pain within first 48 hours and suspected ACS were enrolled to the study. Blood samples were taken for CK-MB, myoglobin, cTnI and H-FABP The patients were divided into two groups (ACS and non ACS). Statistical analyse were used for relation of biomarkers with diagnosis of ACS. RESULTS: A 66 patients were included to the study. H-FAPB values were positive in 15.2% patients. When H-FABP was added to routinely used biomarkers in the diagnosis of ACS, increasing was observed in all sensitivity, specificity, PPV and NPV values. However, this increase was not statistically significant. CONCLUSION: H-FABP did not provide any significant change in early diagnosis and exclusion of ACS diagnosis when used either alone or combination with routinely used biomarkers.
No takes yet. Share an insight, caveat, or question.
Banu et al. (2014) conducted a cross-sectional in Suspected acute coronary syndrome (n=66). H-FABP testing vs. Routinely used biomarkers (myoglobin, CK-MB, cTnI) was evaluated on Diagnostic accuracy (AUC) for acute coronary syndrome (95% CI 0.48-0.73, p=>0.05). H-FABP testing did not provide any statistically significant improvement in the early diagnosis and exclusion of acute coronary syndrome when used alone or in combination with routinely used biomarkers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: